Testing momelotinib plus luspatercept for transfusion-dependent myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a combination of two drugs, momelotinib and luspatercept, for people with myelofibrosis who need regular red blood cell transfusions. The goal is to see if the combination can reduce transfusion needs and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of myelofibrosis (primary or after other blood cancers).
- You have high-risk, intermediate-2, or intermediate-1 myelofibrosis (your doctor can explain this).
- You need regular red blood cell transfusions – at least 4 units in the past 8 weeks, or your hemoglobin is below 8 g/dL at least twice, one week apart.
- You have either not used JAK inhibitors before, or you've used ruxolitinib or fedratinib for at least 90 days (or at least 28 days if you needed transfusions or had bad side effects).
- You have not had your spleen removed, and you don't have serious heart, liver, kidney, bleeding, or other active cancer issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
This trial tests a new combination of two drugs, bomedemstat and momelotinib, for people with myelofibrosis. It aims to see if adding bomedemstat can help when momelotinib alone isn't working well enough, or for those with low blood counts.
This trial tests whether the drug momelotinib, given before and after a stem cell transplant (also called a bone marrow transplant), can help people with myelofibrosis. The hope is that it will make the transplant safer and more effective.
This trial tests two oral medications, momelotinib and ruxolitinib, to see which works better for people with newly diagnosed myelofibrosis who also have low blood cell counts. You may be able to join if your spleen is enlarged and you haven't had prior treatment with certain drugs.
This trial tests a combination of two drugs (pelabresib and ruxolitinib) for people with myelofibrosis whose spleen is enlarged and who have bothersome symptoms. It aims to see if adding pelabresib to standard care helps control the disease better.
Hear when a new Primary Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.